Skip to main content

Table 4 Outcome on kidney angiomyolipoma

From: Rapamycin and its analogues (rapalogs) for Tuberous Sclerosis Complex-associated tumors: a systematic review on non-randomized studies using meta-analysis

Studies Volume (cc) Sum of longest diameter (mm)
Baseline n After treatment n Mean diff (95 % CI) Baseline n After treatment n Mean diff (95 % CI)
Cabrera Lopez 2011 62.6 ± 18.3 17 23.1 ± 7.0 16 −39.5 (−30.15,–48.85)      
Dabora 2011       212 ± 146 36 145 ± 113 28 −67 (−3.55,–130.5)
Davies 2011       135.5 ± 135.6 10 62.8 ± 20.1 7 −69.80 (15.39,–154.99)
Overall Effect      −39.5 (−48.85, −30.15)      −69.03 (−158.05, 12.65)
     p = <0.00001      p = 0.008
Heterogeneity      Not applicable      Chi2 = 0.01; I2 = 0 %